Adicet Bio
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Adicet Bio generated cash of -$93,717, which is more than the previous year. Cash used in financing activities reached the amount of $236 last year. Net change in cash is therefore -$97,945.
Cash Flow
| 2017 | -11.55M | -44K | 64.94M |
|---|---|---|---|
| 2018 | -18.18M | -16.05M | 11.04M |
| 2019 | -27.88M | -47.93M | 76.94M |
| 2020 | -41.70M | 115.21M | 460K |
| 2021 | -51.31M | -2.79M | 242.94M |
| 2022 | -45.12M | -16.78M | 41.87M |
| 2023 | -93.71K | -4.46K | 236 |
0HX7.L Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 257.65K | 277.54M | 84.33M | 10.60M | 7.04M | 0 | 0 |
Operating activities | |||||||
Net income | -142.65K | -69.79M | -61.99M | -36.67M | -28.13M | -9.29M | -33.77M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 6.12K | 5.00M | 4.06M | 1.95M | 1.23M | 1.22M | 5K |
Stock-based compensation expense | 20.25K | 17.12M | 12.51M | 5.26M | 1.17M | 0 | 0 |
| Deferred income tax benefit | 20.25K | 17.12M | 12.51M | 5.26M | 1.17M | 0 | 0 |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 0 | 185K | -30K | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 0 | 1.71M | 1.13M | -814K | 527K | 0 | 1.39M |
Cash generated by operating activities | -93.71K | -45.12M | -51.31M | -41.70M | -27.88M | -18.18M | -11.55M |
Investing activities | |||||||
Purchases Of Investments | 0 | 0 | 0 | -5.7M | -76.07M | 0 | 0 |
Investments In Property Plant And Equipment | -4.46K | -16.78M | -13.04M | -990K | -1.07M | -876K | -44K |
Acquisitions Net | 0 | 0 | 0 | 64.11M | 118K | 0 | 0 |
Cash generated by investing activities | -4.46K | -16.78M | -2.79M | 115.21M | -47.93M | -16.05M | -44K |
Financing activities | |||||||
Common Stock Issued | 0 | 45.10M | 242.94M | 460K | 76.94M | 0 | 64.94M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -150 | -3.23M | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 236 | 41.87M | 242.94M | 460K | 76.94M | 11.04M | 64.94M |
Net Change In Cash | -97.94K | -19.88M | 193.21M | 73.72M | 3.56M | 13.75M | 53.34M |
Cash at end of period | 159.71K | 257.65M | 277.54M | 84.33M | 10.60M | 13.75M | 53.34M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source |